343 related articles for article (PubMed ID: 18473757)
21. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
22. Distinguishing among incretin-based therapies. Introduction.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
[TBL] [Abstract][Full Text] [Related]
23. [New drugs; exenatide and sitagliptin].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
[TBL] [Abstract][Full Text] [Related]
24. Distinguishing among incretin-based therapies. Patient education and self-management.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S28-30. PubMed ID: 20824237
[TBL] [Abstract][Full Text] [Related]
25. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
26. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
27. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
Davidson JA
Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S27-37. PubMed ID: 21106865
[TBL] [Abstract][Full Text] [Related]
28. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes.
McGill JB
Postgrad Med; 2009 Jan; 121(1):46-58. PubMed ID: 19179813
[TBL] [Abstract][Full Text] [Related]
29. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
30. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
31. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
32. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
33. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Van Gaal LF; Gutkin SW; Nauck MA
Eur J Endocrinol; 2008 Jun; 158(6):773-84. PubMed ID: 18322302
[TBL] [Abstract][Full Text] [Related]
34. New therapeutic approaches in type 2 diabetes.
Scheen AJ
Acta Clin Belg; 2008; 63(6):402-7. PubMed ID: 19170358
[TBL] [Abstract][Full Text] [Related]
35. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
Schnabel CA; Wintle M; Kolterman O
Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
[TBL] [Abstract][Full Text] [Related]
36. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
37. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
38. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
González C; Beruto V; Keller G; Santoro S; Di Girolamo G
Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
[TBL] [Abstract][Full Text] [Related]
39. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
40. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]